Join the UCLA CARE Center at AIDS Walk LA & raise support for its mission to provide exceptional state-of-the-art care & conduct clinical trials for people living with HIV & AIDS. All funds raised will benefit the CARE Center. To register or donate, visit https://t.co/zQbEo0sTfo
ACTG announces data from ACTIV-2 study, demonstrating benefit of BRII-196 and BRII-198 in non-hospitalized participants with COVID-19. Congratulations to the team on this important achievement!
https://t.co/fnv2uQK9ls
I began my medical career at the height of the HIV/AIDS crisis, and I've spent my life ever since working to research, treat, and combat infectious diseases.
I'm honored to be called to lead the brilliant team at the CDC. We are ready to combat this virus with science and facts.
Another exciting news this morning, @ViiVHC announces investigational injectable cabotegravir is superior to oral standard of care for HIV prevention in women @HIVptn 084 https://t.co/TwZFTpxY1f
“I’m proud to be part of an organization that recognizes #NLAAD. It’s important to get the word out as Hispanic/Latinos are second among the most affected subpopulation in the US.” – Tina Esquivel, Administrative Specialist, #ACTG LOC
#InThisTogether#HIVAwareness#EndStigma
Information is power! Understanding monoclonal antibodies is vital to understanding #ACTIV2. Check out this video, then visit https://t.co/9g5OdVwOkE for more information about this #COVID19 treatment trial. It's time to #RiseAboveCOVID
Really persuasive perspective from @joshua_schiffer & colleagues on the need for EARLY treatment of #COVID19, especially with antivirals. Very glad @ACTGNetwork protocol A5401/ACTIV-2 specifically is for this patient population. @IDSAInfo@OUPAcademic https://t.co/PaGYc61VkI
“Early treatment of COVID-19 will be vital to help us prevent advanced illness, hospitalization, and transmission of SARS-CoV-2,” said #ACTG Chair Judith Currier, M.D., https://t.co/IePWdnFxgj., #UCLA. #ACTIV2 has launched – learn more at https://t.co/9g5OdVwOkE